3 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 1 | 1 | Unknown 1 |
Follow isoquercitrin: new trials by email Literature Review of isoquercitrin trials Research Report on isoquercitrin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19 Hospital standard of care for COVID-19, Isoquercetin - Covid19 | Phase 2 | Unknown | Nepal Health Research Council | 250 | 2021-02-20 | 2021-02-05 |
| Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 Masitinib, Isoquercetin, Best Supportive Care - SARS-CoV 2, COVID-19 | Phase 2 | Unknown | AB Science | 200 | 2020-06-01 | 2023-02-06 |
| Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial Sunitinib, Isoquercetin, Placebo - Renal Cell Carcinoma, Kidney Cancer | Phase 1 / Phase 2 | Unknown | Consorzio Oncotech | 104 | 2016-11-01 | 2017-01-18 |
COVID-19 (2) · Carcinoma, Renal Cell (1) · Fatigue (1) · Kidney Neoplasms (1)
AB Science (1) · Consorzio Oncotech (1) · Nepal Health Research Council (1)
France (1) · Italy (1)
Giuseppe Di Lorenzo, MD (1) · Pascal Chanez, MD (1)
PMID 21277078, PMID 22045104, PMID 23747347, PMID 36048877, PMID 37117213
2015 (1)